secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001558370-25-011411
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%
-------------------------------------------------------------------

- Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.
- Cash and equivalents of $8.2M as of June 30; cash burn reduced via corporate prioritization.
- FULCRUM-VT pivotal study enrollment surpassed 85% of 206 patients; completion expected H2 2025.
- First-in-human PARALELL PFCA results published in Journal of Cardiovascular Electrophysiology.
- R&D expense down 31% to $2.0M; SG&A down 29% to $2.4M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/0001558370-25-011411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/adgm-20250813x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer